Back to top

Analyst Blog

Sanofi (SNY - Analyst Report) and its subsidiary Genzyme recently announced that their oral candidate for relapsing forms of multiple sclerosis (RMS), Aubagio (teriflunomide), has received US Food and Drug Administration (FDA) approval. The FDA approved Aubagio as a once-daily treatment for patients with RMS. Aubagio is currently under regulatory review in the EU.

FDA approval came in on encouraging data from a pivotal phase III study (TEMSO) in patients with RMS. The TEMSO phase III study evaluated Aubagio in two dosage strengths, 7mg and 14mg. Patients in both 7mg and 14mg Aubagio dosage arms demonstrated a 31% reduction in annualized relapse rate compared to placebo. Additionally, the company presented positive results from the phase III TOWER trial, which was conducted on 1,169 patients with RMS.

However, we note that in the TENERE trial, reported in December 2011, Aubagio failed to show statistical superiority over Pfizer/Merck KGaA’s (PFE - Analyst Report)/(MKGAF) Rebif. There are two more studies in progress, namely TOPIC and TERACLES.

Competition in the oral multiple sclerosis market will be intense and Aubagio needs to demonstrate superior efficacy and tolerability to gain share. Novartis’ (NVS - Analyst Report) Gilenya already has a lead in the oral MS market with the product being approved in September 2010. Another major competitor could be Biogen Idec’s (BIIB - Analyst Report) BG-12, which is currently under regulatory review in the US and EU.

Another RMS candidate, Lemtrada (alemtuzumab), in Sanofi’s portfolio, suffered a setback last month when the FDA issued a refuse-to-file letter in relation to its marketing application. Though the FDA has not asked for any additional studies, Sanofi will have to rework on the presentation of the data. Sanofi plans to work with the FDA and resubmit the marketing application as early as possible.

A marketing application for Lemtrada for RMS was also filed with the European Medicines Agency (EMA), which has been accepted for regulatory review.

We currently have a Neutral recommendation on Sanofi. The stock carries a Zacks #3 Rank (Hold rating) in the short run.

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
SUPER MICRO… SMCI 27.00 +10.25%
CANADIAN SO… CSIQ 38.34 +8.18%
CENTURY ALU… CENX 26.97 +7.97%
WILLDAN GRO… WLDN 11.38 +5.86%
AROTECH COR… ARTX 3.78 +5.59%